Information Provided By: 
Fly News Breaks for February 27, 2018
CLVS
Feb 27, 2018 | 05:01 EDT
Barclays analyst Paul Choi lowered his price target for Clovis Oncology to $85 citing slower market transition to maintenance following the company's Q4 results. The analyst thinks the stock "will likely stay in a holding pattern" prior to the label expansion in the U.S. and an initial treatment indication approval in Europe, both of which are anticipated by Q2. Choi keeps an Overweight rating on Clovis shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
